Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q1 FY20 Earnings Presentation
20 slides from Dr. Lal Pathlabs's earnings presentation, Aug 13, 2019
Slide 1: Exchange filing cover letter for Q1 FY20 presentation
August 13, 2019 The National Stock Exchange of India Limited The Bombay Stock Exchange Limited Exchange Plaza Phiroze Jeejeeboy Towers Sandra Kurla Complex, Sandra (E) Dalal Street, Mumbai - 400051 Mumbai - 400001 Subject: Investors Presentation on Unaudited Financial Results (Standalone and Consoli
Slide 2: Dr. Lal PathLabs Limited Q1 FY20 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q1 FY20 Results Presentation August 13, 2019
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Q1 FY20 Snapshot
Q1 FY20 Snapshot 14.7% 14.5% 19.0% INR 335.2 Cr INR 90.8 Cr INR 59.1 Cr Revenues Normalised EBITDA** PAT 15.9% 19.8% ~4.9 mn ~ 11.9mn Patients Tested Samples Processed * As on March 31, 2019 ** Excluding Ind AS 116 impact 3
Slide 5: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 5 Overview of Dr. Lal PathLabs 6 Key Performance Highlights 7 Financials 8 Financial Highlights 9 Operating Highlights 11 Management Commentary 12 Vibrant Outlook 13 Corporate Overview 14 Shareholding 18 Contact Us 19 DISCLAIMER: This presentation may
Slide 6: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance Professionally managed operations; 7 decades of 16% 20% 25% experience in the world of NO. 1 5-Year Revenue 5-Year PAT CAGR Dividend Payout BRANDED diagnostics CAGR Well diversified outside home NATIONAL market of ‘Delhi NCR’ DIAGNOSTICS 70%+ 58% Zero CHAIN WITH ROCE R
Slide 7: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Established brand Pan-India integrated Varied Offerings Unique and successful coverage operating model 200 clinical labs (including National Reference Lab at Catalogue of 459 test panels, Scalable model integrated Established consumer Delhi and Regional Reference 2,489 p
Slide 8: Key Performance Highlights
Key Performance Highlights Healthy improvement in patient volume trends during Q1 at 15.9% supporting sustained momentum in revenues During Q1 FY20: • Revenues showed increase of 14.7% YoY at Rs 335.2 Cr • Number of patients tested were at 4.9 million • Normalised EBITDA (after eliminating the impac
Slide 9: Financials
Financials Q1 FY20 Q1 FY20 Q1 FY19 Gr % Gr % Particulars (Rs. Cr.) FY'19 (With IND-AS 116) (W/O IND-AS 116) (W/O IND-AS 116) (With IND AS) (W/O IND-AS 116) Revenue 335.2 335.2 292.3 14.7% 14.7% 1,203.4 Other Income 14.4 14.4 9.4 53.2% 53.2% 46.0 Total Income 349.6 349.6 301.7 15.9% 15.9% 1,249.4 Raw
Slide 10: Financial Highlights
Financial Highlights All figures in Rs. Cr 335.2 292.3 Q1 FY20 delivered 14.7% increase in revenues at Rs. 335.2 Cr. This followed: Revenue • Healthy trend in volume growth at 15.9% • Increase in tests per patient from 2.3 to 2.4 Q1 FY20 realisation per patient is at Rs. 684 from Rs. 691 in Q1 F
Slide 11: Financial Highlights
Financial Highlights All figures in Rs. Cr 89.4 75.4 Q1 FY20 PBT at Rs 89.4 Cr vs. Rs. 75.4 last year PBT Q1 FY20 PBT margin at 26.7 % vs. 25.8% last year Q1 FY19 Q1 FY20 59.1 49.7 Q1 FY20 PAT at Rs. 59.1 Cr vs Rs. 49.7 Cr, a growth of 19.0% PAT Q1 FY20 PAT margin at 17.6% vs. 17.0% last yea
Slide 12: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs 2,569 No. of PUPs 200 2,153 189 193 1,759 6,426 5,021 5,624 FY17 FY18 FY19 FY17 FY18 FY19 FY17 FY18 FY19 No. of Patients No. of Samples 17.6 41.8 15.2 34.7 13.3 29.3 4.9 11.9 FY17 FY18 FY19 Q1 FY20 FY17 FY18 FY19 Q1 FY20 11
Slide 13: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “We have grown as a national healthcare services brand on the back of patient centric solutions that we have developed. As we move to the next phase, we will strive to strengthen our n
Slide 14: Vibrant Outlook
Vibrant Outlook Strongly develop Rest of India geographies, through Kolkata National Laboratory and cluster city approach for attractive markets Target to grow Evaluate best fit inorganic Deeper Penetration within the ahead opportunities North, East & Central Indian of the markets industry Higher co
Slide 15: Corporate Overview
Corporate Overview DLPL Strategy for future growth Experienced Management team 14
Slide 16: DLPL Strategy for future growth
DLPL Strategy for future growth 1 2 Strengthen Expansion in Existing Offering Operations 4 3 Expand management of Geographic hospital based expansion and clinical laboratories 15
Slide 17: DLPL Strategy for future growth
DLPL Strategy for future growth Expand management of hospital Strengthen Existing Operations Expansion in Offering Geographic expansion based and clinical laboratories Boosting quality & reliability Improve breadth of Tap incremental contracts for Focus city approach standards diagnostic testing in
Slide 18: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Ved Prakash Goel Bharath Uppiliappan Whole-time Director and Chief Chairman and Managing Director Whole-time Director Chief Financial Officer CEO India Business Executive Officer Shankha Banerjee Munender Soper
Slide 19: Shareholding as of 30th June, 2019
Shareholding as of 30th June, 2019 19.3% FII 14.6% 56.9% Others Promoter and Promoter Group 9.2% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 18
Slide 20: Contact us
Contact us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests